According to the most recent financial data from June 2025, the EPS for the trailing twelve months is $6.97. Iqvia Holdings's EPS for 2024 amounted to $7.57, marking an increase from $7.39 in 2023. During the quarterly period ending on Jun 30, 2025, IQV's EPS stood at $1.55.
Iqvia Holdings had an annual EPS of $7.57, indicating an increase of 2.4% from $7.39 in 2023. The quarterly per-share earnings for the period ending Jun 30, 2025, was $1.55, indicating a 22.1% decrease from the same quarter last year. IQV's 12-month EPS stands at $6.97 as of June 2025. Iqvia Holdings's annual EPS in 2023 stood at $7.39, a 27% increase year-over-year.
Iqvia Holdings has registered a decrease in EPS of 22.1% during the last 12 months (YoY, quarterly). In the last three years, IQV recorded an average annual EPS growth rate of 14.4%. Iqvia Holdings had an average annual EPS growth rate of 50.5% during the last 5 years. Across the last decade, IQV had an average annual EPS growth of 10.5%.
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
IQV Iqvia Holdings Inc | 28.58 | 2.4% | 14.4% | 50.5% |
NWBO Northwest Biotherapeutics Inc | N/A | -16.7% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.